Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).
Allergan plc has updated its second-half 2015 continuing operations financial forecast. The forecast reflects adjustments for the upcoming expected discontinued operations
The National Institutes of Health (NIH) has awarded $46 million for research for the Human Placenta Project, an initiative to revolutionize understanding of the placenta.
The National Institutes of Health (NIH) has awarded nearly $144 million in new grants to develop new tools and measures that can be used to investigate more effectively environmental exposures from the womb through later years in a child’s life.
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.
Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…
Collagen Solutions plc, has announced that its subsidiary Collagen Solutions Inc. has signed a supply agreement with Turkish medical device company Yücel Medikal Ltd.
FDA has announced that the TF Supplements of Houston is voluntarily recalling the following product to the consumer level: RHINO…